RSS
1 2 3

"The beauty of big data is it gives us a lot more insights to be more relevant, more segmented and more targeted. And we can treat more customers in the way they should be treated versus just guessing."

Continue Reading

"The media landscape has been in constant movement over the past few years, which has given us the opportunity to act differently as a challenger. There is the potential to be quicker and smarter, which makes the decision making process faster. Events are happening, and companies must be ready to jump on the train and make something out of it"

Continue Reading

"The smaller companies are trying to look at a space that’s already crowded and struggling to figure out how to optimize the patent filing process and to determine where to invest in innovation. The larger companies have different challenges around monetizing their portfolio and dealing with litigation"

Continue Reading

“I think that changed the way generics operate; since it’s tougher for them to make a lot of money, they’ve gotten even more aggressive.” From the brand perspective “it’s almost impossible to get a settlement that sticks” and that presents challenges across the business.

Continue Reading

“As the expiration dates of several noteworthy drugs are coming ever closer, it is clear that to extend their market life, deep engagement of emerging markets is a necessity. And as the reimbursement environments of emerging markets evolve, the ability to pay for drugs is changing as well, opening up the potential need to build pipelines around disease states that may be unique compared with North America and Europe. With such a substantial opportunity, there are plenty of questions and challenges, and hopefully we can discuss some of them here today.”

Continue Reading

“Knowing when to get outside support is the philosophy throughout the company, not just the legal department. We also have what we call a kitchen cabinet of outside business development advisors who each bring a different perspective to the table and help keep us on target”

Continue Reading

“What’s really needed is a process that keeps options alive so that there’s more than just a “go” or “no-go” choice in a certain phase”.

Continue Reading

Following a number of appeals, Merck wins the U.S. Supreme Court case around the ownership terms of brain-cancer drug Temodar patent.

Continue Reading

‘But we’re not there to steal information from you, from the little company. We’re there to use the information and help us decide about the interest of this investment opportunity.’

Continue Reading